Literature DB >> 10653308

Negative sural nerve biopsy in neurolymphomatosis.

M J van den Bent1, H G de Bruin, G M Bos, G Brutel de la Rivière, P A Sillevis Smitt.   

Abstract

Patients with non-Hodgkin's lymphoma occasionally develop widespread invasion of peripheral nerves by tumor cells or neurolymphomatosis (NL). Clinically this usually results in asymmetrical, progressive, and painful polyneuropathy. Diagnosis rests on the identification of tumor cells in peripheral nerves. To avoid false-negative biopsy findings in patients with malignant lymphomatous infiltration of peripheral nerves it has been recommended to biopsy clinically involved nerves. We present two patients with histologically confirmed NL in whom sural the nerve biopsy finding was negative despite clinical and neurophysiological evidence of involvement of the sural nerve a. The clinical features of NL are reviewed. Some patients with neurolyphomatosis have only focal or proximal involvement of nerves, requiring the biopsy of an affected part of these nerves. Magnetic resonance imaging may be useful in identifying affected nerves.

Entities:  

Mesh:

Year:  1999        PMID: 10653308     DOI: 10.1007/s004150050535

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  Changing PET/CT manifestation of neurolymphomatosis.

Authors:  Klaus Strobel; Bernhard Pestalozzi; Ilja Ciernik; Niklaus G Schaefer; Abbas Yousefi Koma; Thomas F Hany
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-06       Impact factor: 9.236

2.  A case of neurolymphomatosis involving cranial nerves: MRI and fusion PET-CT findings.

Authors:  Ji Hyun Kim; Jae Hong Jang; Seong-Beom Koh
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

3.  Detection of widespread neurolymphomatosis with 18F-FDG PET.

Authors:  Emel Oztürk; Fikret Arpaci; Murat Kocaoğlu; Nuri Arslan; Nail Bulakbaşi; Mehmet Ozgüven
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-16       Impact factor: 9.236

4.  Lymphomatous meningosis diagnosed with [18F]-fluorodeoxyglucose-positron-emission tomography/CT.

Authors:  S Ceyssens; T Van den Wyngaert; P Blockx; L van den Hauwe; P M Parizel; L van den Hauwe; K Geens
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-03       Impact factor: 3.825

5.  Assessment of neurolymphomatosis by brachial plexus biopsy and PET/CT. Report of a case.

Authors:  Felix Bokstein; Odelyia Goor; Boris Shihman; Shimon Rochkind; Einat Even-Sapir; Ur Metser; Miri Neufeld
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

6.  Fusion PET-CT detection of neurolymphomatosis originating from primary breast lymphoma: A case report and literature review.

Authors:  Liying Xu; Yunfeng Zhou; Dasheng Qiu; Salman Shams
Journal:  Oncol Lett       Date:  2012-08-03       Impact factor: 2.967

7.  [Neurolymphomatosis. Subacute sensorimotor polyneuropathy as a first sign of non-Hodgkin's B cell lymphoma].

Authors:  P P Urban; E Kaczmarek; I Wellach; R Brüning; N Brüllke; C Schulte; K Knop; J Weis
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

8.  Progressive neurolymphomatosis with cutaneous disease: response in a patient with mycosis fungoides.

Authors:  Ramez Hanna; Gina A Di Primio; Mark Schweitzer; Carlos Torres; Adnan Sheikh; Santanu Chakraborty
Journal:  Skeletal Radiol       Date:  2013-03-27       Impact factor: 2.199

9.  Imaging of non-neurogenic peripheral nerve malignancy-a case series and systematic review.

Authors:  Rodrigo Luna; Laura M Fayad; Fausto J Rodriguez; Shivani Ahlawat
Journal:  Skeletal Radiol       Date:  2020-07-23       Impact factor: 2.199

10.  Diagnostic utility of FDG-PET in neurolymphomatosis: report of five cases.

Authors:  Hisanori Kinoshita; Hodaka Yamakado; Toshiyuki Kitano; Akihiro Kitamura; Hirofumi Yamashita; Masakazu Miyamoto; Takefumi Hitomi; Tomohisa Okada; Yuji Nakamoto; Nobukatsu Sawamoto; Akifumi Takaori-Kondo; Ryosuke Takahashi
Journal:  J Neurol       Date:  2016-06-10       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.